TYRX Envelope, WRAP-IT Study

STRATEGIES TO REDUCE CIED INFECTION DURING A PANDEMIC AND BEYOND – IMPLICATIONS OF THE WRAP-IT STUDY RESULTS

THURSDAY, SEPTEMBER 17th, 2020

5 p.m. PDT | 6 p.m. MDT | 7 p.m. CDT | 8 p.m. EDT (45 minutes in length)

PROGRAM DESCRIPTION

Join Dr. Bruce Wilkoff, Dr. Khaldoun Tarakji, and Dr. Suneet Mittal, as they discuss the latest strategies to reduce cardiac implantable electronic device infections, thereby reducing readmission rates and decreasing hospitalization during a global pandemic.

PROGRAM OBJECTIVES

Review evidence on the incidence and consequences of CIED infection
Explore strategies to reduce CIED infection, including TYRX™ technology and learnings from the WRAP-IT Study
Discuss implications of reducing infections during a global pandemic
Discuss with the audience in a live virtual, interactive Q&A format

MODERATOR

Rob Kowal, M.D., Ph.D, Vice President, Medical Affairs and Business Development, Chief Medical Officer, Cardiac Ablation Solutions, Cardiac Rhythm & Heart Failure, Medtronic, Mounds View, Minnesota

FACULTY

Bruce Wilkoff, M.D., Director of Cardiac Pacing and Tachyarrhythmia Devices, Professor of Medicine, Cleveland Clinic, Cleveland Ohio

Khaldoun Tarakji,l, M.D., M.P.H., Cleveland Clinic Director, Heart and Vascular Institute Center for Digital Health and Telemedicine, Cleveland Clinic, Cleveland Ohio

Suneet Mittal, M.D., F.A.C.C., F.H.R.S., Director, Electrophysiology, Valley Health System, Ridgewood, New Jersey

TARGET AUDIENCE

Electrophysiologists, Cardiologists, Infectious Disease Specialists, Allied Health Professionals, and Cardiology/ Electrophysiology Fellows from around the world.

*View Indications, Safety and Warnings US

*View Indications, Safety and Warnings EU

REGISTRATION

Complete the form below to register for the upcoming Global Grand Rounds program. You will receive a confirmation email with detailed login information to use on the day of the program and will be emailed reminders prior to the start of the event.

Email Address*

First Name*

Last Name*

Account Affiliation*

Country/Region*

Type of HCP*

How did you hear about the program?*

I agree to receive future email messages about Global Grand Rounds webcasts at Medtronic.*

I have read and agree with the Terms and Conditions below.*

Brief Statement

The TYRX™ Absorbable Antibacterial Envelope is intended to hold a pacemaker pulse generator or defibrillator securely in order to provide a stable environment when implanted in the body. The TYRX Absorbable Antibacterial Envelope contains the antimicrobial agents minocycline and rifampin, which have been shown to reduce infection in an in vivo model of bacterial challenge following surgical implantation of the generator or defibrillator. The TYRX Absorbable Antibacterial Envelope is NOT indicated for use in patients who have an allergy or history of allergies to tetracyclines, rifampin, or absorbable sutures. The TYRX Absorbable Antibacterial Envelope is also NOT indicated for use in patients with contaminated or infected wounds, or Systemic Lupus Erythematosus (SLE). The use of this product in patients with compromised hepatic and renal function, or in the presence of hepatotoxic or renal toxic medications, should be considered carefully, because minocycline and rifampin can cause additional stress on the hepatic and renal systems. Patients who receive the TYRX Absorbable Antibacterial Envelope and who are also taking methoxyflurane should be monitored carefully for signs of renal toxicity.

Your information will be used and protected in accordance with our privacy statement.